Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Viral And Non-Viral Vector Manufacturing Market?
The market size for manufacturing of viral and non-viral vectors has seen significant growth in the past few years. The market project’s growth from $8.67 billion in 2024 to $10.3 billion in 2025, with a compound annual growth rate (CAGR) of 18.8%. The exponential growth during the historical period is credited to the heightened occurrence of genetic disorders, advancements in biotech, increased funding in gene therapy research, greater understanding of personalized medicine, and regulations that support the development of gene therapy.
What Growth Rate Is Forecasted for the Viral And Non-Viral Vector Manufacturing Market by 2029?
In the forthcoming years, the market for viral and non-viral vector manufacturing is projected to witness substantial expansion. The market is predicted to swell to a size of $22.06 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 21.0%. This surge during the forecast timeframe can be credited to escalating demands for gene therapies, enlargement of applications in the treatment of rare diseases, mounting investments in the biomanufacturing infrastructure, and an uptick in the embracing of precision medicine. Key emerging patterns in the forecast span comprise the creation of next-generation viral vectors, amplifying usage of CRISPR or cas9 technology in vector manufacturing, emphasis on scalable and cost-effective manufacturing procedures, accelerated adoption of non-viral vectors, and advancements in cell and gene therapy manufacturing techniques.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12570&type=smp
Which Key Companies Are Shaping the Future of the Viral And Non-Viral Vector Manufacturing Market?
Major companies operating in the viral and non-viral vector manufacturing market include Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.
Which Factors Are Driving Demand in the Viral And Non-Viral Vector Manufacturing Industry?
The rising incidence of genetic disorders is anticipated to spur the expansion of the viral and non-viral vector manufacturing markets. Genetic disorders are usually caused by a shift from the normal DNA sequence. Viral vectors are employed to convey therapeutic genes to target cells, substituting or augmenting the faulty genes that trigger genetic disorders. Non-viral vectors are typically used in ex vivo gene therapy methods, in which cells are genetically altered outside the body and then reintroduced into the patient. For example, in June 2022, the International Diabetes Federation, based in Belgium, reported that global diabetes prevalence had risen to 10.5%, with more than half (44.7%) remaining undiagnosed, and about 783 million adults, or every one out of eight persons, anticipated to be diabetic by 2045. Thus, the escalating occurrence of genetic disorders fuels the growth of the viral and non-viral vector manufacturing market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12570&type=smp
How Is the Viral And Non-Viral Vector Manufacturing Market Segmented by Several Divisions?
The viral and non-viral vector manufacturing market covered in this report is segmented –
1) By Vector Type: Viral Vector, Non-Viral Vector
2) By Disease: Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases
3) By Application: Gene Therapy, Vaccinology, Cell Therapy, Other Applications
Subsegments:
1) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Other Viral Vectors
2) By Non-Viral Vector: Plasmid DNA, Lipid-Based Vectors, Nanoparticles, Electroporation-Based Vectors, Other Non-Viral Vectors
What are the Emerging Market Trends Driving the Growth of the Viral And Non-Viral Vector Manufacturing Industry?
The viral and non-viral vector manufacturing markets are increasingly influenced by the trend of technological advancements. Several leading companies in these markets are creating cutting-edge solutions to maintain their market standing. For example, in August 2022, Merck KGaA, a science and technology company based in Germany, unveiled the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. They are among the pioneers as a Contract development and manufacturing organization and technology provider, offering a comprehensive viral vector manufacturing solution, which includes AAV, Lentiviral, CDMO, CTO, and process development. This revolutionary platform enables biopharmaceutical companies to reduce both the duration and costs associated with process development, while also hastening the transition to clinical manufacture.
Access The Full Report Here:
Which Regions Are Driving Growth in the Viral And Non-Viral Vector Manufacturing Market?
North America was the largest region in the viral and non-viral vector manufacturing market in 2024. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12570
This Report Delivers Insight On:
1. How big is the viral and non-viral vector manufacturing market, and how is it changing globally?
2. Who are the major companies in the viral and non-viral vector manufacturing market, and how are they performing?
3. What are the key opportunities and risks in the viral and non-viral vector manufacturing market right now?
4. Which products or customer segments are growing the most in the viral and non-viral vector manufacturing market?
5. What factors are helping or slowing down the growth of the viral and non-viral vector manufacturing market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
